Tags

Type your tag names separated by a space and hit enter

Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
Diabet Med. 2007 Nov; 24(11):1254-60.DM

Abstract

AIMS

Thiazolidinediones may influence the atherogenic process by improving cardiovascular risk factors. The present study was designed to determine the long-term effect of rosiglitazone on arterial compliance and metabolic parameters in patients with Type 2 diabetes.

METHODS

In an open-label, prospective study, 65 diabetic patients received rosiglitazone orally (4-8 mg/day) for 6 months. After 6 months, the patients continued an open follow-up study and were divided into two groups: group 1 included patients continuing rosiglitazone for 2 years, group 2 included patients discontinuing rosiglitazone and receiving other oral glucose-lowering agents. Lipid profile, glycated haemoglobin (HbA1c), insulin, C-peptide, fibrinogen, high-sensitivity-CRP and homeostasis model assessment-insulin resistance were measured. Arterial elasticity was assessed using pulse wave contour analysis.

RESULTS

In patients treated with rosiglitazone for 2 years: the large artery elasticity index (LAEI) increased from 10.0 +/- 4.6 to 13.9 +/- 4.7 ml/mmHg x 100 after 2 years (P = 0.003). The small artery elasticity (SAEI) index increased significantly from 3.2 +/- 1.2 to 5.1 +/- 1.9 (P < 0.0001). In patients who discontinued rosiglitazone: LAEI did not change after 6 months, but decreased from 12.1 +/- 5.4 to 8.9 +/- 3.9 ml/mmHg x 10 (P < 0.0001) at the end of 2 years. SAEI increased during the first 6 months of treatment, from 3.9 +/- 1.8 to 5.1 +/- 1.5 ml/mmHg x 100 (P < 0.0001) and decreased after discontinuation of rosiglitazone (P = 0.042).

CONCLUSIONS

Prolonged treatment with rosiglitazone improved arterial elasticity. However, significant deterioration in LAEI and SAEI was observed in patients who discontinued rosiglitazone. The beneficial vascular effect of rosiglitazone on arterial elasticity was independent of glycaemic control.

Authors+Show Affiliations

Department of Endocrinology, Brunner Institute for Cardiovascular Research, Wolfson Medical Center Holon and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17725634

Citation

Shargorodsky, M, et al. "Effect of Long-term Treatment With Rosiglitazone On Arterial Elasticity and Metabolic Parameters in Patients With Type 2 Diabetes Mellitus: a 2-year Follow-up Study." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 24, no. 11, 2007, pp. 1254-60.
Shargorodsky M, Michaelova K, Boaz M, et al. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study. Diabet Med. 2007;24(11):1254-60.
Shargorodsky, M., Michaelova, K., Boaz, M., Gavish, D., & Zimlichman, R. (2007). Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study. Diabetic Medicine : a Journal of the British Diabetic Association, 24(11), 1254-60.
Shargorodsky M, et al. Effect of Long-term Treatment With Rosiglitazone On Arterial Elasticity and Metabolic Parameters in Patients With Type 2 Diabetes Mellitus: a 2-year Follow-up Study. Diabet Med. 2007;24(11):1254-60. PubMed PMID: 17725634.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study. AU - Shargorodsky,M, AU - Michaelova,K, AU - Boaz,M, AU - Gavish,D, AU - Zimlichman,R, Y1 - 2007/08/24/ PY - 2007/8/30/pubmed PY - 2008/4/11/medline PY - 2007/8/30/entrez SP - 1254 EP - 60 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet Med VL - 24 IS - 11 N2 - AIMS: Thiazolidinediones may influence the atherogenic process by improving cardiovascular risk factors. The present study was designed to determine the long-term effect of rosiglitazone on arterial compliance and metabolic parameters in patients with Type 2 diabetes. METHODS: In an open-label, prospective study, 65 diabetic patients received rosiglitazone orally (4-8 mg/day) for 6 months. After 6 months, the patients continued an open follow-up study and were divided into two groups: group 1 included patients continuing rosiglitazone for 2 years, group 2 included patients discontinuing rosiglitazone and receiving other oral glucose-lowering agents. Lipid profile, glycated haemoglobin (HbA1c), insulin, C-peptide, fibrinogen, high-sensitivity-CRP and homeostasis model assessment-insulin resistance were measured. Arterial elasticity was assessed using pulse wave contour analysis. RESULTS: In patients treated with rosiglitazone for 2 years: the large artery elasticity index (LAEI) increased from 10.0 +/- 4.6 to 13.9 +/- 4.7 ml/mmHg x 100 after 2 years (P = 0.003). The small artery elasticity (SAEI) index increased significantly from 3.2 +/- 1.2 to 5.1 +/- 1.9 (P < 0.0001). In patients who discontinued rosiglitazone: LAEI did not change after 6 months, but decreased from 12.1 +/- 5.4 to 8.9 +/- 3.9 ml/mmHg x 10 (P < 0.0001) at the end of 2 years. SAEI increased during the first 6 months of treatment, from 3.9 +/- 1.8 to 5.1 +/- 1.5 ml/mmHg x 100 (P < 0.0001) and decreased after discontinuation of rosiglitazone (P = 0.042). CONCLUSIONS: Prolonged treatment with rosiglitazone improved arterial elasticity. However, significant deterioration in LAEI and SAEI was observed in patients who discontinued rosiglitazone. The beneficial vascular effect of rosiglitazone on arterial elasticity was independent of glycaemic control. SN - 0742-3071 UR - https://www.unboundmedicine.com/medline/citation/17725634/Effect_of_long_term_treatment_with_rosiglitazone_on_arterial_elasticity_and_metabolic_parameters_in_patients_with_Type_2_diabetes_mellitus:_a_2_year_follow_up_study_ DB - PRIME DP - Unbound Medicine ER -